Rainbow Children's Medicare Limited Just Recorded A 8.0% Revenue Beat: Here's What Analysts Think

Rainbow Children's Medicare Limited (NSE:RAINBOW) just released its quarterly report and things are looking bullish. Results were good overall, with revenues beating analyst predictions by 8.0% to hit ₹4.7b. Statutory earnings per share (EPS) came in at ₹5.97, some 2.3% above whatthe analysts had expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Rainbow Children's Medicare after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the latest results, Rainbow Children's Medicare's 14 analysts are now forecasting revenues of ₹20.7b in 2027. This would be a meaningful 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to expand 15% to ₹32.21. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹20.0b and earnings per share (EPS) of ₹31.98 in 2027. There doesn't appear to have been a major change in sentiment following the results, other than the small increase to revenue estimates.

View our latest analysis for Rainbow Children's Medicare

It may not be a surprise to see thatthe analysts have reconfirmed their price target of ₹1,682, implying that the uplift in revenue is not expected to greatly contribute to Rainbow Children's Medicare's valuation in the near term. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Rainbow Children's Medicare analyst has a price target of ₹2,000 per share, while the most pessimistic values it at ₹1,459. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Rainbow Children's Medicare's past performance and to peers in the same industry. The analysts are definitely expecting Rainbow Children's Medicare's growth to accelerate, with the forecast 18% annualised growth to the end of 2027 ranking favourably alongside historical growth of 15% per annum over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 18% per year. Rainbow Children's Medicare is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also upgraded their revenue forecasts, although the latest estimates suggest that Rainbow Children's Medicare will grow in line with the overall industry. The consensus price target held steady at ₹1,682, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Rainbow Children's Medicare going out to 2029, and you can see them free on our platform here..

You can also see whether Rainbow Children's Medicare is carrying too much debt, and whether its balance sheet is healthy, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.